嵌合抗原受体T细胞疗法治疗多发性骨髓瘤的研究进展

Research progress in chimeric antigen receptor T cell therapy for multiple myeloma

多发性骨髓瘤(multiple myeloma,MM)是由浆细胞恶性增殖引起的恶性肿瘤,可在骨髓中积累导致骨髓衰竭.MM的治疗通常包括免疫调节剂和造血干细胞移植等方式,但是疗效并不理想.嵌合抗原受体T细胞疗法是近年来出现的一种新型免疫疗法,通过体外基因编辑技术改造患者的T细胞,使其能够特异性识别肿瘤细胞的表面抗原,从而达到靶向杀伤肿瘤细胞的目的.此文主要就嵌合抗原受体T细胞在MM治疗中的应用及靶点作一介绍.

Multiple myeloma(MM)is a malignant tumor caused by malignant proliferation of plasma cells,which accumulates in the bone marrow and leads to bone marrow failure.Treatment for MM usually involves immunomodulators and hematopoietic stem cell transplantation,but the response is not ideal.Chimeric antigen receptor(CAR)T cell therapy is a new type of immunotherapy emerging in recent years.In which,T cells from patients are modified by in vitro gene editing technology to specifically recognize the surface antigens of tumor cells,so as to achieve target killing of tumor cells.This article mainly introduces the application and targets of CAR-T cells in the treatment of MM.